Introducing the F3 Platform Biologics Team
The F3 Team is comprised of experts with decades of experience in research and development of amifostine applications, a proven track record of successful execution and performance in a variety of companies, from start-ups to large publicly traded institutions, a history of successfully commercializing scientific products, extensive medical practice and specialization in radiation physics, radiation oncology, medical oncology and cancer treatment, and deep experience in managing both start-up and established pharmaceutical companies
Executive Team
Jonathan Peskoff
Chief Executive Officer & Co-Founder
Mr. Peskoff has more than 25 years of experience maximizing value and guiding organizational growth for companies as an executive officer, entrepreneur, senior investment banker, venture capitalist and individual investor …
Jonathan D. Rosen
Founder, Chief Executive Officer and Chairman Emeritus
Jonathan D. Rosen, our former Chief Executive Officer and Chairman, had more than 20 years of experience as an executive and business leader, serving as Founder, CEO, and Chairman of Entaire Global Companies, Inc. prior to its sale to Synovus Bank in 2016 …
Patrick Fennell
Director of Corporate Development
Mr. Fennell currently serves as the Director of Corporate Development for F3 Platform Biologics and has provided services for the Company in various capacities since 2021. Mr. Fennell brings more than 8 years of financial services and advisory experience …
Board of Directors
Daniel Courchesne, Chairman
Daniel Courchesne has served as a director since October 4, 2019. Mr. Courchesne is currently President of Synovus’ Specialty Finance Division which includes the Asset Based Lending, Structured Lending and Global One divisions of Synovus Bank …
Scientific Advisory Team
Dr. David Grdina
Co-Chair
Dr. David Grdina, co-chair of our SAB, is an expert in the field of radiation biophysics and heads the Grdina Laboratory at the University of Chicago…
Dr. David I. Rosenthal
Co-Chair
Dr. David I. Rosenthal is a Professor of Radiation Oncology and Head & Neck Surgery at The University of Texas MD Anderson Cancer Center in Houston, Texas…
Dr. David Brenner
Dr. Brenner studied radiation physics at the Medical College of St. Bartholomew’s Hospital, University of London, and obtained a PhD from the University …
Dr. Winston Marshall
Dr. Marshall is a board-certified cardiologist in the areas of cardiovascular disease and interventional cardiology …
Dr. Archie Bleyer
Dr. Bleyer is renowned for his pediatric oncology medical contributions. A University of Rochester School of Medicine and Dentistry graduate …
Dr. Jeffrey Murley
Jeffrey S. Murley, PhD is a Research Associate and Associate Professor in the Department of Radiation and Cellular Oncology at The University of Chicago …
Dr. Richard Albertini
Dr. Albertini is a Research Professor in the Department of Pathology at the University of Vermont. He has been a professor in the pathology field for …
Dr. Donald P. Frush
Dr. Frush is the John Strohbehn Professor of Radiology, and an Associate Faculty Member, Medical Physics Graduate Program at Duke University Medical Center …
Dr. Michael I. Koukourakis
Dr. Koukourakis is a Professor of Radiation Oncology, and Head of the Department of Radiotherapy and Oncology, Medical School, Democritus University of Thrace …
Dr. Randall A. Stenoien
Dr. Stenoien is CEO of Houston Medical Imaging with 8 locations in the greater Houston area and the Rio Grande Valley. Dr. Stenoien has a vast knowledge of interventional and oncology experience …
Dr. James Dziadziola Jr.
Dr. James Dziadziola Jr. is an otolaryngologist in Kannapolis, North Carolina and is affiliated with multiple hospitals in the area …
Mr. Viren Grover
Mr. Viren Grover joined our Scientific Advisory Group in 2019, bringing a wealth of experience of more than 40 years …
Dr. Ralph Boccia
Dr. Ralph Boccia is the President and Medical Director of the Center for Cancer and Blood Disorders, in Bethesda, Maryland. Dr. Boccia also holds positions as Clinical Associate Professor …
Strategic Alliances
University of Chicago
F3 has a worldwide, exclusive license to amifostine-related intellectual property developed at the University of Chicago by the co-chair of our Scientific Advisory Board (“SAB”), Dr. David Grdina …